Pfizer Quietly Adds Warning That 'Unfavorable Pre-Clinical, Clinical Or Safety Data' May Impact Business

As we get closer and closer to the day that the FDA has to release its first batch of 55,000 pages of clinical trial documents, it looks like Pfizer is bracing for impact. That’s because it was just revealed that Pfizer updated its fourth-quarter investor report—the section on potential risks to their business. Specifically, they added that in the near future, information regarding the quality of pre-clinical, clinical, or safety data that might be released by an audit or inspection might be a threat to their business. Meanwhile, while I was in Texas, I took the opportunity to sit down and speak with Jim Lamon, the founder of an America-first renewable energy company, and we discussed the way forward for American energy independence. Stay tuned for our newsletter so you won’t miss out on our exclusive videos and private events. Facts Matter is an Epoch Times show available on YouTube. Follow Roman on Instagram: @epoch.times.roman Listen to Podcasts: iTunes Podcast: https://ept.ms/FactsMatterApplePodcast Spotify Podcast: https://ept.ms/FactsMatterSpotifyPodcast Google Podcast: https://ept.ms/FactsMatterGooglePodcast Follow EpochTV on social media: Facebook: https://www.facebook.com/EpochTVus Twitter: https://twitter.com/EpochTVus Rumble: https://rumble.com/c/EpochTV Gettr: https://gettr.com/user/epochtv Gab: https://gab.com/EpochTV Telegram: https://t.me/EpochTV Parler: https://parler.com/#/user/EpochTV